ClinicalTrials.gg
RecruitingNCT06846554ViTAL-PHUpdated May 11, 2026

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

A Phase 2 interventional study of APL-9796 and APL-9796 in Pulmonary Arterial Hypertension, sponsored by Apollo Therapeutics Ltd. Recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Apollo Therapeutics Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom — 11 open to participants now, 18 under way, 6 of them phase 3. Pulmonary Arterial Hypertension · United Kingdom.

Planned enrollment
65th of 91
48 · median 108
Started
2025
with 1 other
Phase 2
25 of 98
3 open now
Primary completion
2027-08
later than 7 of 17 live
Registered
90th of 98
by date

Among the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom, this one is the 65th largest by planned enrollment of the 91 interventional ones that give a count, is one of 2 that started in 2025, is one of 25 in phase 2, reaches primary completion later than 7 of the 17 other live ones, and was the 90th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

11 of the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796.

The trial will be conducted in two parts:

  • Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH).
  • Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).
03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Hypertension
  • WHO group 3
  • WHO group 1 PH
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 to 80 years of age inclusive
  2. Participants who are diagnosed with pulmonary hypertension via right heart catheterisation (RHC), documented at any time prior to Screening.
  3. WHO Functional Class II or III
  4. Participant has the CardioMEMS PA Sensor implanted.

Exclusion criteria

Exclusion Criteria:

  1. Hospital admission related to PH within 3 months prior to Screening.
  2. Major surgical procedure within 3 months prior to Screening, unless participant is assessed as completely recovered by the Investigator
  3. Diagnosis of PH due to , portal hypertension, schistosomiasis, or uncorrected congenital heart disease
  4. History of left-sided heart disease and/or cardiac disease
  5. History of uncontrolled systemic hypertension
  6. ≤30 ml/min/1.73m2
  7. of \< 12 months, as assessed by the Investigator
  8. Diagnosed with a within 5 years of enrolment
  9. to protocol-required imaging (MRI), diagnostic, or sampling methods
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Part A: in adults with WHO Group 1 PAH.

    Three (3) APL-9796 dose levels are planned for evaluation using BOIN design.

    Drug: APL-9796

  • Experimental
    Part B (optional): in adults with WHO Group 3 PH-ILD

    Cohorts will be enrolled sequentially at N=4, at a dose level determined by the Safety Review Committee (SRC) based on data from Part A.

    Drug: APL-9796

Interventions

  • DrugAPL-9796

    3 Cohorts are planned in Part A.

  • DrugAPL-9796

    The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Number of participants who experience Treatment-Emergent Adverse Events will be reported which also include the frequency, severity (CTCAE V5.0) and relationship (causality) of AEs

    Time frame: Through study completion (approximately 2 years)

Secondary outcomes

  1. To assess the Telemetry Parameters

    Telemetry parameter is assessed using Total pulmonary resistance (TPR)

    Time frame: from baseline (CFB) to Day 169

  2. To assess the Telemetry Parameters

    Telemetry parameter is assessed using Pulmonary arterial pressures: systolic, diastolic and mean (mPAP)

    Time frame: from baseline (CFB) to Day 169

  3. To assess Six minute walk test / Six minute walk distance (6MWD)

    A 6-minute walk test (6MWT) is assessed per the guidelines of the American Thoracic Society 2003

    Time frame: from baseline (CFB) to Day 169

  4. To assess NT-proB-type Natriuretic Peptide (NT-proBNP)

    The level of NT-proBNP is assessed by blood sample collection and analysis

    Time frame: from baseline (CFB) to Day 169

  5. To assess the Quality of life

    Quality of life is assessed using SF-36 questionnaire

    Time frame: from baseline (CFB) to Day 169

  6. To assess the Quality of life

    Quality of life is assessed using emPHasis-10 questionnaire

    Time frame: from baseline (CFB) to Day 169

  7. To evaluate the PK of APL-9796 in participants with PH

    APL-9796 concentrations in serum

    Time frame: at each visit (approximately every 28 days until day 169), then day 254, day 339 and day 508

  8. To evaluate the immunogenicity of APL-9796 in participants with PH.

    * Incidence of anti-drug antibody (ADA) against APL-9796 (including titres) * Incidence of neutralising antibody (Nab) against APL-9796 (including titres)

    Time frame: at each visit (approximately every 28 days until day 169), then day 254, day 339 and day 508

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2027, 28 months after the start.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 28 months is close to that.

Counting every sponsor, half of 52 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Feb 26, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Aug 30, 2027
CompletionEst.
Sep 30, 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06846554
Lead sponsor
Apollo Therapeutics Ltd
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Apr 9, 2025
Primary completion
Aug 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
May 11, 2026

Study contacts

Sanjay Aggarwal, MD
Contact
AP13@apollotx.com
781-479-2267

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion